Synthego has tapped Eurofins Genomics to distribute synthetic single guide RNA products from its CRISPRevolution line of genome-editing kits.

LEO Pharma signed on to a research collaboration with PellePharm that commits up to $760 million for late-stage trials, including a merger option.

Eli Lilly VP Robert Brown is making the jump to serve as CEO of the skin disease-focused Brickell Biotech.

Merck KGaA is launching a new joint venture with the tech firm Palantir, built around a collaboration platform for cancer research and discovery.

In rodent studies, exon skipping corrected a genetic error that's responsible for kidney disease linked to Joubert syndrome.

Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.

Results from Aimmune’s phase 3 trial of AR101 for peanut allergy have been published and bode well for its planned FDA filing next month.

The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases.

The deal gives the Roche subsidiary at least a partial stake in the preclinical MAGE-A4-targeting drug IMC-C103C.